Content uniformity of quartered hydrocortisone tablets in comparison with mini-tablets for paediatric dosing
暂无分享,去创建一个
Matthew Roberts | Matthew Peak | J. Blair | M. Roberts | J. Ford | James L Ford | M. Peak | Jude Madathilethu | Joanne Blair | Rebecca Prescott | Jude Madathilethu | R. Prescott
[1] I. Wong,et al. When Do Children Convert from Liquid Antiretroviral to Solid Formulations? , 2005, Pharmacy World and Science.
[2] J. Fell,et al. The tensile strength of lactose tablets , 1968, The Journal of pharmacy and pharmacology.
[3] G. Slegers,et al. Statistical analysis of tablet breakability methods. , 2002, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.
[4] Anette Müllertz,et al. Dissolution of Hydrocortisone in Human and Simulated Intestinal Fluids , 2000, Pharmaceutical Research.
[5] J. Breitkreutz,et al. Acceptability of Uncoated Mini-Tablets in Neonates--A Randomized Controlled Trial. , 2015, The Journal of pediatrics.
[6] R L Carr,et al. EVALUATING FLOW PROPERTIES OF SOLIDS , 1965 .
[7] Matthew Roberts,et al. Development and evaluation of sustained-release Compritol® 888 ATO matrix mini-tablets , 2012, Drug development and industrial pharmacy.
[8] S. Eksborg,et al. Dividing the Tablets for Children – Good or Bad? , 2016 .
[9] Izabel Calland Ricarte Beserra,et al. Health related quality of life of children and adolescents with congenital adrenal hyperplasia in Brazil , 2014, Health and Quality of Life Outcomes.
[10] K. Kachrimanis,et al. Flow rate of some pharmaceutical diluents through die-orifices relevant to mini-tableting. , 2005, International journal of pharmaceutics.
[11] M. Dattani,et al. Deconvolution analysis of 24‐h serum cortisol profiles informs the amount and distribution of hydrocortisone replacement therapy , 2011, Clinical endocrinology.
[12] M. Mclean,et al. Prolonged Hypocortisolemia in Hydrocortisone Replacement Regimens in Adrenocorticotrophic Hormone Deficiency , 2007, Pediatrics.
[13] G. Chrousos,et al. Hydrocortisone suspension and hydrocortisone tablets are not bioequivalent in the treatment of children with congenital adrenal hyperplasia. , 2001, The Journal of clinical endocrinology and metabolism.
[14] H W Frijlink,et al. Breaking of scored tablets: a review. , 2002, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[15] D. Gibb,et al. Young HIV-Infected Children and Their Adult Caregivers Prefer Tablets to Syrup Antiretroviral Medications in Africa , 2012, PloS one.
[16] Jörg Breitkreutz,et al. Favorable acceptance of mini-tablets compared with syrup: a randomized controlled trial in infants and preschool children. , 2013, The Journal of pediatrics.
[17] J. Breitkreutz,et al. Acceptance of uncoated mini-tablets in young children: results from a prospective exploratory cross-over study , 2012, Archives of Disease in Childhood.
[18] P. Hindmarsh,et al. Working memory performance is reduced in children with congenital adrenal hyperplasia , 2015, Hormones and Behavior.
[19] J. Ford,et al. Manipulation of drugs to achieve the required dose is intrinsic to paediatric practice but is not supported by guidelines or evidence , 2013, BMC Pediatrics.
[20] W. Miller. Consensus statement on 21-hydroxylase deficiency from the Lawson Wilkins Pediatric Endocrine Society and the European Society for Paediatric Endocrinology. , 2002, The Journal of clinical endocrinology and metabolism.
[21] J. Ford,et al. A systematic review of the use of dosage form manipulation to obtain required doses to inform use of manipulation in paediatric practice. , 2017, International journal of pharmaceutics.
[22] George P Chrousos,et al. Children with classic congenital adrenal hyperplasia have elevated serum leptin concentrations and insulin resistance: potential clinical implications. , 2002, The Journal of clinical endocrinology and metabolism.
[23] P. Murgatroyd,et al. Insulin sensitivity and body composition in children with classical and nonclassical congenital adrenal hyperplasia , 2010, Clinical endocrinology.
[24] H. Dörr,et al. Obesity Among Children and Adolescents With Classic Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency , 2006, Pediatrics.
[25] Canary Wharf,et al. List of criteria for screening PIPs with regard to paediatric specific Quality issues and referring them to the PDCO FWG for discussion , 2013 .
[26] Matthew Roberts,et al. Production of extended release mini-tablets using directly compressible grades of HPMC , 2013, Drug development and industrial pharmacy.
[27] D. Eckland,et al. Development and testing in healthy adults of oral hydrocortisone granules with taste masking for the treatment of neonates and infants with adrenal insufficiency. , 2015, The Journal of clinical endocrinology and metabolism.
[28] O. Decker,et al. Influence of hydrocortisone dosage scheme on health‐related quality of life in patients with adrenal insufficiency , 2010, Clinical endocrinology.
[29] K. Lackner,et al. Alterations in Lipid and Carbohydrate Metabolism in Patients with Classic Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency , 2010, Hormone Research in Paediatrics.
[30] P. Hindmarsh,et al. Bioavailability of oral hydrocortisone in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. , 2001, The Journal of endocrinology.
[31] P. Hindmarsh,et al. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency: alterations in cortisol pharmacokinetics at puberty. , 2001, The Journal of clinical endocrinology and metabolism.